For a long time, proinflammatory factors such as TNF‐α and IL‐6 in IBD patients have aroused people's attention, and monoclonal antibodies or small‐molecule drugs targeting specific cytokines or their receptors have been used to treat IBD. The gene discussed is IL6; the disease is inflammatory bowel disease.